Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7441 to 7455 of 7707 results

  1. Masitinib for the treatment of locally advanced or metastatic pancreatic cancer [ID566]

    Discontinued [GID-TAG330]

    Technology appraisal guidance
    Discontinued

  2. Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]

    Discontinued [GID-TAG337]

    Technology appraisal guidance
    Discontinued

  3. Cetuximab for the treatment of advanced non-small-cell lung cancer [ID9]

    Discontinued [GID-TAG395]

    Technology appraisal guidance
    Discontinued

  4. Venous leg ulcers - new treatments [ID394]

    Discontinued [GID-TAG370]

    Technology appraisal guidance
    Discontinued

  5. Venous thromboembolism (VTE) - ximelagatran [ID396]

    Discontinued [GID-TAG378]

    Technology appraisal guidance
    Discontinued

  6. Intensity modulated radiotherapy for breast cancer [ID16]

    Discontinued [GID-TAG390]

    Technology appraisal guidance
    Discontinued

  7. Intensity modulated radiotherapy for prostate cancer [ID17]

    Discontinued [GID-TAG396]

    Technology appraisal guidance
    Discontinued

  8. Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]

    Discontinued [GID-TAG399]

    Technology appraisal guidance
    Discontinued

  9. Thrombophilia [ID393]

    Discontinued [GID-TAG374]

    Technology appraisal guidance
    Discontinued

  10. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued [GID-TAG402]

    Technology appraisal guidance
    Discontinued

  11. Drugs for the treatment of pulmonary arterial hypertension [ID12]

    Discontinued [GID-TAG382]

    Technology appraisal guidance
    Discontinued

  12. Atrial fibrillation - ximelagatran [ID376]

    Discontinued [GID-TAG377]

    Technology appraisal guidance
    Discontinued

  13. Diabetic retinopathy - ruboxistaurin [ID382]

    In development [GID-TAG386] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

    In development [GID-TAG406] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

    Discontinued [GID-TAG363]

    Technology appraisal guidance
    Discontinued